Immature platelet fraction (IPF) as a prognostic biomarker towards platelet count recovery in adult dengue patients: A systematic review and meta-analysis

Abstract

Dengue is a viral infection spread by arthropod which will damage platelets and caused thrombocytopenia. An increase production of platelets from bone marrow to compensate thrombocytopenia can be measured using IPF (immature platelet fraction). Therefore, this study aims to synthesize information about the potential of immature platelet fraction as a prognostic biomarker towards predicting platelet recovery. We search article study from online databases (PubMed, Cochrane, Google Scholar, and Scopus) using keywords dengue and immature platelet fraction. Three independent reviewers were screened and extracted data about prognostic potential of IPF% towards platelet count. IPF% generally moves in a manner mirroring platelet count change. IPF% increase and platelet count decrease were generally seen until day 4-8, followed by a reversal – IPF% decrease and platelet count increase on the following days. Previous research had also shown that platelet recovery may be seen within 24 to 48 hours post maximum IPF% measurement. This systematic review identified IPF% as a significant prognostic to platelet recovery in adult dengue patients. Knowledge about how to utilize IPF% will help clinicians to avoid prescribing unnecessary platelet transfusions.

Keywords

• Immature Platelet Fraction
• Dengue
• Prognosis
• Systematic Review
• Meta-Analysis

References

1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature. 2013 Apr;496(7446):504–7.
2. Elkady A, Sinha P, Hassan SAZ. Dengue Fever. Infect Pregnancy An Evidence-Based Approach. 2019 Aug;60–2.
3. Tantawichien T, Thisayakorn U. Dengue. Neglected Trop Dis - South Asia. 2017;329.
4. Khetarpal N, Khanna I. Dengue Fever: Causes, Complications, and Vaccine Strategies. J Immunol Res. 2016;2016.
5. Katzelnick LC, Gresh L, Halloran ME, Mercado JC, Kuan G, Gordon A, et al. Antibody-dependent enhancement of severe dengue disease in humans. Science (80- ). 2017 Nov;358(6365):929–32.
6. Bethell DB, Gamble J, Loc PP, Dung NM, Chau TTH, Loan HT, et al. Noninvasive measurement of microvascular leakage in patients with dengue hemorrhagic fever. Clin Infect Dis. 2001 Feb;32(2):243–53.
7. De Azeredo EL, Monteiro RQ, De-Oliveira Pinto LM. Thrombocytopenia in dengue: Interrelationship between virus and the imbalance between coagulation and fibrinolysis and inflammatory mediators. Mediators Inflamm. 2015;2015.
8. Shah D, Khataniar M, Sawhney A, Nautiyal M, Desai R, Kakar A. An observational study to see the correlation between trends of platelet counts and immature platelet fraction in dengue infection. Trop Doct. 2021;51(3):378–81.

9. Lyde RB, Poncz M, Lambert MP. Platelet Transfusion. Platelets Thromb Non-Thrombotic Disord Pathophysiol Pharmacol Ther an Updat. 2022 May;1391–401.
10. Agarwal M, Bansal PK, Yadav ML. Utility of immature platelet fraction to predict platelet recovery in dengue patients having thrombocytopenia. Int J Adv Med. 2021;8(3):410.
11. Bongiovanni D, Han J, Klug M, Kirmes K, Viggiani G, Von Scheidt M, et al. Role of Reticulated Platelets in Cardiovascular Disease. Arterioscler Thromb Vasc Biol. 2022 May;42(5):527–39.
12. Dadu T, Sehgal K, Joshi M, Khodaiji S. Evaluation of the immature platelet fraction as an indicator of platelet recovery in dengue patients. Int J Lab Hematol. 2014;36(5):499–504.
13. Moons KGM, de Groot JAH, Bouwmeester W, Vergouwe Y, Mallett S, Altman DG, et al. Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies: The CHARMS Checklist. PLoS Med. 2014;11(10).
14. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021 Mar;372.
15. Worldometers.info. Indonesia Population. Worldometers.Info. 2017. p. 1.
16. Yasuda I, Saito N, Suzuki M, Umipig DV, Solante RM, de Guzman F, et al. Unique characteristics of new complete blood count parameters, the Immature Platelet Fraction and the Immature Platelet Fraction Count, in dengue
17. Chakraborty S, Alam S, Sayem M, Sanyal M, Das T, Saha P, et al. Investigation of the efficacy and safety of eltrombopag to correct thrombocytopenia in moderate to severe dengue patients - a phase II randomized controlled clinical trial. EClinicalMedicine. 2020 Dec;29–30:100624.
18. Ahmad W, Lubna Z, Mohsin A, Nishat A. Study of platelet indices in dengue fever with thrombocytopenia and correlation of immature platelet fraction (IPF) with platelet recovery. Arch Hematol Case Reports Rev. 2020 Jan;5(1):001–5.
19. Puspita RI, Hadi U, Arfijanto MV, Rusli M, Bramantono, Miftahussurur M. Immature platelet fraction and platelet counts changes in dengue fever patients. New Armen Med J. 2019;13(1):64–8.
20. Looi KW, Matsui Y, Kono M, Samudi C, Kojima N, Ong JX, et al. Evaluation of immature platelet fraction as a marker of dengue fever progression. Int J Infect Dis. 2021;110:187–94.
21. Cochrane Bias Methods Group, Cochrane Non-Randomised Studies Methods Group. Risk of bias tools. 2020.
22. Bhatt P, Sabeena SP, Varma M, Arunkumar G. Current Understanding of the Pathogenesis of Dengue Virus Infection. Curr Microbiol. 2021 Jan;78(1):17–32.
23. Chao CH, Wu WC, Lai YC, Tsai PJ, Perng GC, Lin YS, et al. Dengue virus nonstructural protein 1 activates platelets via Toll-like receptor 4, leading to thrombocytopenia and hemorrhage. PLoS Pathog. 2019;15(4):e1007625.
24. Guzman MG, Harris E. Dengue. Lancet. 2015;385(9966):453–65.
25. Ghiasi H, Perng GC, Nesburn AB, Wechsler SL. Antibody-dependent enhancement of HSV-1 infection by anti-gK sera. Virus Res. 2000;
26. Chen R, Vasilakis N. Dengue-Quo tu et quo vadis? Viruses. 2011;3(9):1562–608.
27. World Health Organization. Dengue guidelines for diagnosis, treatment, prevention and control. World Health Organization. 2009.
28. Goel G, Semwal S, Khare A, Joshi D, Amerneni CK, Pakhare A, et al. Immature Platelet Fraction: Its Clinical Utility in Thrombocytopenia Patients. J Lab Physicians. 2021 Sep;13(03):214–8.
29. Huang HL, Chen CH, Kung C Te, Li YC, Sung PH, You HL, et al. Clinical utility of mean platelet volume and immature platelet fraction in acute coronary syndrome. Biomed J. 2019 Apr;42(2):107–15.
30. Hong KH, Kim HK, Kim JE, Jung JS, Han KS, Cho HI. Prognostic value of immature platelet fraction and plasma thrombopoietin in disseminated intravascular coagulation. Blood Coagul Fibrinolysis. 2009 Sep;20(6):409–14.
31. Muronoi T, Koyama K, Nunomiya S, Lefor AK, Wada M, Koinuma T, et al. Immature platelet fraction predicts coagulopathy-related platelet consumption and mortality in patients with sepsis. Thromb Res. 2016 Aug;144:169–75.
32. Larruzea Ibarra A, Munõz Marín L, Perea Durán G, Torra Puig M. Evaluation of immature platelet fraction in patients with myelodysplastic syndromes. Association with poor prognosis factors. Clin Chem Lab Med. 2019 Jun;57(6):E128–30.